PhoreMost Overview
- Founded
-
2014
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$46M
- Investors
-
15
PhoreMost General Information
Description
Developer of a drug target identification platform intended to identify new targets or drugs for future therapy. The company's platform provides cryptic druggable sites in the human genome and directly links them to useful therapeutic functions in a live-cell context and then uses these functionally validated protein fragments to rapidly inform the design of small molecule drugs with the same shape, enabling medical practitioners to continue the pipeline of highly validated first-in-class drug discovery programs for out-licensing to pharma.
Contact Information
Website
www.phoremost.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Drug Discovery
Primary Office
- Unit 7, The Works
- Unity Campus
- Pampisford CB22 3FT
- England, United Kingdom
+44 01223 000000
PhoreMost Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series B) | 23-Mar-2021 | $46M | 000.00 | 00000 | Completed | Generating Revenue |
| 5. Early Stage VC (Series A) | 30-Apr-2018 | 000.00 | 000.00 | 000.00 | Completed | Pre-Clinical Trials |
| 4. Grant | 27-Apr-2018 | 00.000 | Completed | Pre-Clinical Trials | ||
| 3. Early Stage VC | 03-Mar-2017 | 00.000 | 00.000 | 000.00 | Completed | Pre-Clinical Trials |
| 2. Grant | 13-May-2015 | $2.14M | $6.12M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 11-Mar-2015 | $6.12M | $6.12M | Completed | Pre-Clinical Trials |
PhoreMost Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| A1 Ordinary | 000,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | |
| A Ordinary | 0,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| A Ordinary | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| A Ordinary | 46,700 | $0.001393 | $59.66 | $59.66 | 1x | $59.66 | 7.83% | |
| A Ordinary | 65,311 | $0.001393 | $54.18 | $54.18 | 1x | $54.18 | 10.96% |
PhoreMost Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of a drug target identification platform intended to identify new targets or drugs for future therapy. The com
Discovery Tools (Healthcare)
Pampisford, United Kingdom
50
As of 2023
000.00
0000
0000-00-00
00000000000
000.00
000000
sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labor
0000 000000000
Quincy, MA
00
As of 0000
000
0000
0000-00-00
000000&0
000
00000
m, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conse
0000000000000
San Diego, CA
00
As of 0000
000.00
00000000000
000.00
Add Comparison
PhoreMost Competitors (68)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abveris | Formerly VC-backed | Quincy, MA | 00 | 000 | 000000&0 | 000 |
| 00000 0000000 0000 | Formerly VC-backed | San Diego, CA | 00 | 000.00 | 00000000000 | 000.00 |
| 000000 000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 00000 | 00000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Boston, MA | 00 | 00000 | 000000000 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000000000 | 00000 |
PhoreMost Patents
PhoreMost Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202111193-D0 | Pharmaceutical compounds | Pending | 03-Aug-2021 | 000000000 | |
| GB-202110820-D0 | Targeted protein degradation | Inactive | 28-Jul-2021 | ||
| EP-3969605-A1 | Method of screening for peptides capable of binding to a ubiquitin protein ligase (e3) | Pending | 13-May-2019 | 0000000000 | |
| GB-201906705-D0 | Methods | Inactive | 13-May-2019 | 0 | |
| US-20220236273-A1 | Method of screening for peptides capable of binding to a ubiquitin protein ligase (e3) | Pending | 13-May-2019 | G01N33/574 |
PhoreMost Executive Team (10)
PhoreMost Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alastair Kilgour | Parkwalk Advisors | Board Member | 000 0000 |
| Catherine Beech MD | Self | Chairman | 000 0000 |
| Christopher Torrance Ph.D | PhoreMost | Co-Founder & Chairman | 000 0000 |
| Gerald Chan Ph.D | Morningside Group | Board Member | 000 0000 |
| Hermann Hauser Ph.D | Amadeus Capital Partners | Board Member | 000 0000 |
PhoreMost Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PhoreMost Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| 5Y Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Astellas Venture Management | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| BGF | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
| Trend Investment Group | Venture Capital | Minority | 000 0000 | 000000 0 | |
| XtalPi | VC-Backed Company | Minority | 000 0000 | 000000 0 |